Concept information
Terme préférentiel
Ipilimumab
Type
-
mesh:Descriptor
Définition
- An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
Concept générique
Synonyme(s)
- 6T8C155666
- Anti-CTLA-4 MAb Ipilimumab
Qualificatif(s) autorisé(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- analysis (Qualifier)
- biosynthesis (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- drug effects (Qualifier)
- economics (Qualifier)
- genetics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- physiology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- ultrastructure (Qualifier)
- urine (Qualifier)
Action(s) pharmacologique(s)
Traductions
-
français
-
6T8C155666
-
Anti-CTLA-4 MAb Ipilimumab
-
Anticorps monoclonal anti-CTLA-4 Ipilimumab
URI
http://data.loterre.fr/ark:/67375/JVR-V4LF9LPH-N
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}